

ORIGINAL ARTICLE

# Association of estimated glucose disposal rate with erectile dysfunction: mediating role of neutrophil-to-lymphocyte ratio

Hesong Pan, Feng Chen\* and Lulu Pan\*

The Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People's Hospital, Wenzhou city, China

## Popular scientific summary

- Lower estimated glucose disposal rate (a non-invasive insulin resistance indicator) is significantly associated with higher erectile dysfunction prevalence;
- Linear, more prominent in higher-educated men, outperforms traditional indices;
- Neutrophil-to-lymphocyte ratio-reflected inflammation mediates 10.3%.

## Abstract

**Background:** Insulin resistance (IR) has been established as an independent risk factor for erectile dysfunction (ED).

**Objective:** This study aimed to investigate the association between the estimated glucose disposal rate (eGDR) – a simple and non-invasive surrogate measure of IR – and the prevalence of ED.

**Design:** This cross-sectional study analyzed data from the National Health and Nutrition Examination Survey (NHANES)

conducted between 2001 and 2004. The association between ED prevalence and eGDR was assessed using receiver operating characteristic analysis, multivariate logistic regression, restricted cubic spline (RCS) regression, and subgroup analysis. In addition, the mediating role of the neutrophil-to-lymphocyte ratio (NLR) in the eGDR–ED relationship was evaluated through mediation analysis.

**Results:** A total of 3,774 subjects were included, of whom 1,072 (28.4%) had ED. Multivariate logistic regression analysis revealed that eGDR was significantly and inversely associated with the risk of ED (odds ratios = 0.85, 95% confidence intervals [CI]: 0.78, 0.92). Subgroup analyses indicated that this association was more pronounced among individuals with higher educational attainment. RCS regression confirmed a linear inverse relationship. Furthermore, eGDR demonstrated superior discriminative performance for ED (area under the curve [AUC] = 0.705, 95% CI: 0.679, 0.731) compared with traditional IR and obesity indices. Mediation analysis showed that NLR mediated 10.3% (95% CI: 2.3%, 25.2%) of the total association between eGDR and ED.

**Conclusion:** This study provides the first evidence of a significant inverse association between eGDR and ED prevalence, with NLR serving as a partial mediator.

**Keywords:** *estimated glucose disposal rate; obesity; erectile dysfunction; insulin resistance; diabetes mellitus*

Received: 10 April 2026; Revised: 15 June 2026; Accepted: 16 June 2026; Published: 28 August 2026

Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse (1). It is a highly prevalent condition, particularly among men aged  $\geq 40$  years (2). Data from the Massachusetts Male Aging Study indicate that the overall prevalence of moderate, mild, and complete ED was 52% among men aged 40–70 years (3). ED may arise from organic or psychogenic factors, and both mechanisms frequently coexist in affected individuals (4). Numerous comorbidities and risk factors are significantly associated

with ED, including physical inactivity, obesity, alcohol consumption, smoking, dyslipidemia, diabetes mellitus, hypogonadism, and hypertension. Furthermore, ED has been identified as a potential predictor of coronary heart disease (CHD), cardiovascular disease (CVD), and stroke (2, 5, 6). Collectively, ED imposes a substantial health burden on aging men. A substantial body of observational evidence has confirmed a significant association between ED and diabetes mellitus, with insulin resistance (IR) serving as a key underlying mechanism (7). Vascular endothelial dysfunction is pivotal in the

pathogenesis of ED (8), and IR represents a primary driver of this process.

The estimated glucose disposal rate (eGDR), derived from readily obtainable clinical parameters – including waist circumference (WC), glycated hemoglobin A1c (HbA1c), and hypertension status – has been proposed as a straightforward surrogate marker of IR in individuals with type 1 diabetes mellitus (T1DM) (9). Previous research has extended the application of eGDR to patients with T2DM, acute ischemic stroke, and non-diabetic populations, demonstrating significant associations between eGDR and various outcomes, including diabetic complications, CVD, and all-cause mortality (10–13). However, the relationship between eGDR and ED remains inadequately characterized.

Given the established role of eGDR as an indicator of IR, we hypothesized that eGDR is inversely associated with the prevalence of ED. To investigate this relationship, we conducted a cross-sectional study using data from the National Health and Nutrition Examination Survey (NHANES).

## Methods

### Research population

The NHANES is a comprehensive, nationally representative research initiative overseen by the National Center for Health Statistics (NCHS) (14), designed to evaluate the interrelationships among disease prevention, health promotion, and nutrition. The survey employs a combination of structured interviews, physical examinations, and laboratory assessments to collect demographic, dietary, laboratory, and examination data.

This study utilized data from NHANES cycles conducted between 2001 and 2004. Male participants meeting the inclusion criteria were initially identified ( $n = 10,301$ ). Exclusion criteria were applied sequentially: age < 18 years ( $n = 4,760$ ), missing data on ED status ( $n = 1,425$ ) or eGDR ( $n = 298$ ), and missing information on hypertension, diabetes, stroke, or CHD ( $n = 44$ ). The final analytical cohort comprised 3,774 subjects (Fig. 1).

### Calculation of IR and obesity surrogate markers

The following IR and obesity surrogate markers were calculated using simple anthropometric and biochemical measurements:

$$eGDR \text{ (mg/kg/min)} = 21.158 - (0.09 \times WC \text{ [cm]}) - (3.407 \times \text{hypertension}) - (0.551 \times HbA1c \text{ [\%]}).$$

In this study, hypertension was coded as 0 (absent) or 1 (present) (15). Although the eGDR formula was originally developed for patients with T1DM, its


application has been subsequently extended to patients with T2DM.

$$METS-IR = BMI \text{ (kg/m}^2\text{)} \times \ln[\text{fasting TG (mg/dL)} + (2 \times \text{fasting glucose [mg/dL]})] / \ln[HDL-C \text{ (mg/dL)}] \text{ (16)}$$

$$TyG = \ln[\text{fasting TG (mg/dL)} \times \text{fasting glucose (mg/dL)} / 2] \text{ (17)}$$

$$\text{Waist-to-height ratio (WHtR)} = WC / \text{height}$$

$$\text{Body mass index (BMI)} = \text{weight (kg)} / \text{height (m)}^2$$



**Fig. 1.** Flowchart of the sample selection from the 2001 to 2004 NHANES. eGDR: estimated glucose disposal rate; CHD: coronary heart disease.

### Assessment of ED

ED was assessed using a single-item measure derived from the Massachusetts Male Aging Study (18). Participants were asked: 'Many men encounter difficulties with sexual intercourse. How would you characterize your capacity to achieve and maintain an erection adequate for satisfactory intercourse?' Response options included: 'Usually able', 'Always or almost always able', 'Never able', and 'Sometimes able'. For analytical purposes, participants who responded 'Never able' or 'Sometimes able' were classified as having ED, whereas those who reported being 'Usually able' or 'Always or almost always able' were categorized as not having ED.

### Measurement of covariates

Based on previous studies (15, 16), the final analytical model incorporated potential confounding factors associated with both eGDR and ED. Demographic variables included age, race, height, weight, WC, educational attainment, physical activity, and poverty-to-income ratio (PIR). Questionnaire data encompassed smoking status, diabetes mellitus, alcohol consumption, stroke, CHD, and hypertension. Laboratory biomarkers included total cholesterol (TC), uric acid, low-density lipoprotein cholesterol (LDL-C), neutrophil count, triglycerides (TG), creatinine, lymphocyte count, high-density lipoprotein cholesterol (HDL-C), and albumin. The neutrophil-to-lymphocyte ratio (NLR) was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count (19).

### Statistical analysis

Subjects were stratified into quartiles based on eGDR values (Q1:  $\leq 6.00$ ; Q2: 6.00–8.69; Q3: 8.69–9.88; Q4:  $\geq 9.88$ ). Mobile examination center (MEC) weights were used to obtain prevalence estimates that were representative of the US population. Given the data spanned two survey cycles from 2001 to 2004, MEC weights  $\times 0.5$  were applied as the final weights. The association between ED and eGDR was evaluated using weighted-multiple logistic regression models, with results presented as odds ratios (ORs) and 95% confidence intervals (CIs). Three distinct models were constructed: Model 1 (unadjusted); Model 2 (adjusted for race and age); and Model 3 (comprehensively adjusted for age, race, alcohol consumption, smoking, CHD, stroke, creatinine, PIR, educational level, TG, marital status, albumin, and uric acid). Multicollinearity was assessed using the variance inflation factor (VIF), with a  $VIF \geq 5$  indicating significant multicollinearity. None of the covariates exhibited multicollinearity (Table 1).

The potential influence of covariates on the eGDR–ED association was further explored through weighted subgroup and interaction analyses. The non-linear relationship between ED and eGDR was examined using weighted restricted cubic spline (RCS) curves.

**Table 1.** Collinearity statistics

| Variable          | VIF  |
|-------------------|------|
| eGDR              | 1.16 |
| Age               | 1.42 |
| Race              | 1.56 |
| PIR               | 1.44 |
| Marital status    | 1.43 |
| Educational level | 1.78 |
| CHD               | 1.09 |
| Stroke            | 1.06 |
| Smoking           | 1.09 |
| Drinking          | 1.09 |
| TG                | 1.06 |
| Creatinine        | 1.11 |
| Albumin           | 1.10 |
| Uric acid         | 1.12 |

VIF: variance inflation factor; eGDR: estimated glucose disposal rate; PIR: poverty-to-income ratio; CHD: coronary heart disease; TG: triglycerides.

The proportion of the mediating effect attributable to NLR was quantified using weighted mediation analysis with the 'mediation' R package. Both the mediator model and the outcome model simultaneously controlled for the confounding factors included in Model 3. Using 1,000 non-parametric bootstrap resamples, the direct effect (DE), indirect effect (IE), and total effect (TE) were estimated, and the mediating proportion was calculated as  $(IE / TE \times 100\%)$ . Given the observational design and cross-sectional assessment of variables, these assumptions cannot be formally tested and should be interpreted with caution.

Receiver operating characteristic (ROC) analysis was performed to evaluate the diagnostic performance of eGDR, HbA1c, METS-IR (metabolic score for insulin resistance), BMI (body mass index), TyG (triglyceride-glucose index), WHtR (waist to height ratio), and WC for ED. The DeLong test was used to compare area under the curves (AUCs) between markers. Incremental predictive value was assessed by comparing a baseline model (age only) with an eGDR-augmented model using: 1) C-statistic (DeLong test); 2) continuous net reclassification improvement (NRI); and 3) integrated discrimination improvement (IDI). In a sensitivity analysis, ED was redefined more stringently by including only participants who responded 'Never able' to maintain an erection. All statistical analyses were performed using Free Statistics software and R software.

## Results

### Baseline characteristics

A total of 3,774 subjects, ranging in age from 18 to 85 years, were included. Of these, 1,072 (28.4%) reported ED.

**Table 2.** Characteristics of the study population based on erectile dysfunction, weighted

| Characteristic                     | Overall <i>n</i> = 52,890,592<br><i>N</i> = 3,774 | No ED <i>n</i> = 42,425,981<br><i>N</i> = 2,702 | ED <i>n</i> = 10,464,611<br><i>N</i> = 1,072 | <i>P</i> |
|------------------------------------|---------------------------------------------------|-------------------------------------------------|----------------------------------------------|----------|
| Age                                | 45.45 (16.09)                                     | 41.51 (13.60)                                   | 61.40 (15.57)                                | <0.001   |
| Race, <i>n</i> (%)                 |                                                   |                                                 |                                              | 0.188    |
| Mexican American                   | 4004342.7 (7.6)                                   | 3279360.2 (7.7)                                 | 724982.5 (6.9)                               |          |
| Other Hispanic                     | 2448573.6 (4.6)                                   | 1888061.7 (4.5)                                 | 560511.9 (5.4)                               |          |
| Non-Hispanic White                 | 39145467.8 (74.0)                                 | 31061742.1 (73.2)                               | 8083725.7 (77.2)                             |          |
| Non-Hispanic Black                 | 5152273.1 (9.7)                                   | 4333347.4 (10.2)                                | 818925.7 (7.8)                               |          |
| Other race                         | 2139935.5 (4.0)                                   | 1863470.1 (4.4)                                 | 276465.4 (2.6)                               |          |
| Education level, <i>n</i> (%)      |                                                   |                                                 |                                              | <0.001   |
| Less than high school              | 9282408.0 (17.6)                                  | 6121751.4 (14.4)                                | 3160656.6 (30.2)                             |          |
| High school or above               | 43564149.5 (82.4)                                 | 36260194.8 (85.6)                               | 7303954.6 (69.8)                             |          |
| Marital, <i>n</i> (%)              |                                                   |                                                 |                                              | <0.001   |
| Married/living with partner        | 36950651.7 (69.9)                                 | 28806158.0 (67.9)                               | 8144493.7 (77.8)                             |          |
| Separated/divorced/widowed         | 6166316.3 (11.7)                                  | 4648846.0 (11.0)                                | 1517470.2 (14.5)                             |          |
| Never married                      | 9769536.0 (18.5)                                  | 8966888.7 (21.1)                                | 802647.3 (7.7)                               |          |
| Alcohol status, <i>n</i> (%)       |                                                   |                                                 |                                              | 0.032    |
| Current or ever, %                 | 44751657.5 (84.6)                                 | 36187198.4 (85.3)                               | 8564459.1 (81.8)                             |          |
| Never                              | 8119423.5 (15.4)                                  | 6219271.4 (14.7)                                | 1900152.1 (18.2)                             |          |
| Smoking status, <i>n</i> (%)       |                                                   |                                                 |                                              | <0.001   |
| Current or ever, %                 | 30252165.9 (57.2)                                 | 23201132.8 (54.7)                               | 7051033.1 (67.4)                             |          |
| Never                              | 22632695.7 (42.8)                                 | 19221389.3 (45.3)                               | 3411306.4 (32.6)                             |          |
| Hypertension, <i>n</i> (%)         |                                                   |                                                 |                                              | <0.001   |
| No                                 | 39024014.4 (73.8)                                 | 33678994.5 (79.4)                               | 5345019.9 (51.1)                             |          |
| Yes                                | 13866578.3 (26.2)                                 | 8746986.9 (20.6)                                | 5119591.3 (48.9)                             |          |
| Diabetes, <i>n</i> (%)             |                                                   |                                                 |                                              | <0.001   |
| No                                 | 48340647.6 (91.4)                                 | 40378144.8 (95.2)                               | 7962502.8 (76.1)                             |          |
| Yes                                | 3953836.1 (7.5)                                   | 1600076.5 (3.8)                                 | 2353759.6 (22.5)                             |          |
| CHD, <i>n</i> (%)                  |                                                   |                                                 |                                              | <0.001   |
| No                                 | 50169774.2 (94.9)                                 | 41296880.7 (97.3)                               | 8872893.6 (84.8)                             |          |
| Yes                                | 2720818.4 (5.1)                                   | 1129100.8 (2.7)                                 | 1591717.6 (15.2)                             |          |
| Stroke, <i>n</i> (%)               |                                                   |                                                 |                                              | <0.001   |
| No                                 | 51862048.7 (98.1)                                 | 42152025.1 (99.4)                               | 9710023.6 (92.8)                             |          |
| Yes                                | 1028543.9 (1.9)                                   | 273956.3 (0.6)                                  | 754587.6 (7.2)                               |          |
| Body mass index, kg/m <sup>2</sup> | 27.97 (5.33)                                      | 27.81 (5.26)                                    | 28.64 (5.58)                                 | 0.025    |
| Waist circumference, cm            | 99.96 (14.59)                                     | 98.88 (14.33)                                   | 104.38 (14.78)                               | <0.001   |
| HbA1c, %                           | 5.52 (0.90)                                       | 5.42 (0.75)                                     | 5.94 (1.24)                                  | <0.001   |
| Albumin, g/dL                      | 43.74 (2.91)                                      | 44.05 (2.83)                                    | 42.46 (2.90)                                 | <0.001   |
| Total cholesterol, mmol/L          | 5.12 (4.45, 5.79)                                 | 5.15 (4.47, 5.84)                               | 5.02 (4.40, 5.61)                            | 0.053    |
| Triglycerides, mmol/L              | 1.43 (0.99, 2.18)                                 | 1.39 (0.97, 2.09)                               | 1.60 (1.12, 2.51)                            | <0.001   |
| HDL-cholesterol, mmol/L            | 1.16 (1.00, 1.40)                                 | 1.16 (0.98, 1.40)                               | 1.19 (1.01, 1.41)                            | 0.229    |
| LDL-cholesterol, mmol/L            | 3.05 (2.46, 3.67)                                 | 3.08 (2.50, 3.70)                               | 2.90 (2.31, 3.36)                            | <0.001   |
| Creatinine, umol/L                 | 88.40 (79.56, 97.24)                              | 88.40 (79.56, 97.24)                            | 88.40 (79.56, 106.08)                        | 0.024    |
| Uric acid, umol/L                  | 356.90 (309.30, 410.40)                           | 356.90 (309.30, 410.40)                         | 356.90 (309.30, 416.40)                      | 0.535    |
| PIR                                | 3.25 (1.57)                                       | 3.32 (1.57)                                     | 2.98 (1.53)                                  | <0.001   |
| NLR                                | 2.25 (0.84)                                       | 2.18 (0.75)                                     | 2.51 (1.09)                                  | <0.001   |
| eGDR                               | 8.23 (2.39)                                       | 8.57 (2.20)                                     | 6.82 (2.62)                                  | <0.001   |

For continuous variables: survey-weighted mean (SD) or median (IQR). For categorical variables: survey-weighted *n* (%). HDL-c: High density lipoprotein cholesterol; LDL-c: Low density lipoprotein cholesterol; PIR: poverty-income ratio; eGDR: estimated glucose disposal rate; CHD: coronary heart disease; NLR: neutrophil-to-lymphocyte ratio; HbA1c: hemoglobin A1c.

Subjects with ED had significantly lower eGDR values than those without ED. Men with ED were more likely to be older, have lower educational attainment, be married or living with a partner, have a lower PIR, and exhibit higher BMI, WC, HbA1c, TG, and NLR. They also were more frequently former smokers, and had higher prevalences of diabetes, stroke, hypertension, and CHD (all  $P < 0.05$ ). Comprehensive demographic and clinical characteristics are presented in Table 2.

#### Association between eGDR and ED

To investigate the association between eGDR and ED, three multivariate weighted logistic regression models were constructed (Table 3). Model 1 (unadjusted) identified a statistically significant inverse association between eGDR and ED. This inverse association persisted after comprehensive adjustment for all covariates in Model 3 (OR = 0.85, 95% CI: 0.78, 0.92). In the sensitivity analysis with eGDR categorized into quartiles, participants in the fourth quartiles demonstrated statistically significant 58% reductions in ED risk, compared with those in the lowest quartile (Model 3). RCS analysis illustrated a linear inverse association between eGDR and ED prevalence (Fig. 2).

#### Subgroup analysis

The robustness of the eGDR–ED association was assessed through extensive interaction tests and subgroup analyses to identify potential effect modification across diverse subpopulations (Fig. 3). The results demonstrated a consistent significant association between eGDR and ED across most subgroups. Notably, this association was more pronounced among individuals with higher educational attainment.


#### Mediating role of NLR

Mediation analysis confirmed the mediating role of NLR in the eGDR–ED association. The results indicated that

10.3% (95% CI: 2.3–25.2%) of the observed association between eGDR and ED risk was mediated through NLR (Fig. 4; Table 4).

#### Predictive value of eGDR for ED

The ROC curve analysis (Fig. 5) evaluated the diagnostic performance of eGDR, HbA1c, METS-IR, BMI, TyG, WHtR, and WC for ED. As shown in Table 5, eGDR exhibited the highest discrimination for ED, with an AUC of 0.705 (95% CI: 0.679–0.731), significantly outperforming other IR and obesity surrogate markers ( $P < 0.001$ ).




**Fig. 2.** Restricted cubic spline fitting for the association between eGDR levels and ED. Adjusted for age, race, drinking, smoking, CHD, stroke, creatinine, PIR, education level, TG, marital status, albumin, and uric acid. eGDR: estimated glucose disposal rate; ED: erectile dysfunction; CI: confidence intervals; OR: odds ratios; PIR: poverty-income ratio; CHD: coronary heart disease; TG: triglycerides.

**Table 3.** Weighted-multivariable logistic regression for the association between eGDR and ED


| Subgroups       | Model 1           |        | Model 2           |        | Model 3           |       |
|-----------------|-------------------|--------|-------------------|--------|-------------------|-------|
|                 | OR (95% CI)       | P      | OR (95% CI)       | P      | OR (95% CI)       | P     |
| eGDR            | 0.74 (0.70, 0.78) | <0.001 | 0.86 (0.81, 0.91) | <0.001 | 0.85 (0.78, 0.92) | 0.003 |
| eGDR (category) |                   |        |                   |        |                   |       |
| Q1              | I (Ref)           |        | I (Ref)           |        | I (Ref)           |       |
| Q2              | 0.47 (0.35, 0.64) | <0.001 | 0.61 (0.43, 0.84) | <0.001 | 0.72 (0.41, 1.28) | 0.202 |
| Q3              | 0.29 (0.20, 0.40) | <0.001 | 0.38 (0.28, 0.51) | <0.001 | 0.45 (0.25, 0.79) | 0.015 |
| Q4              | 0.12 (0.08, 0.18) | <0.001 | 0.56 (0.35, 0.88) | 0.016  | 0.42 (0.18, 0.96) | 0.043 |
| P for trend     |                   | <0.001 |                   | <0.001 |                   | 0.001 |

Model 1: None covariates were adjusted; Model 2: race and age were adjusted; Model 3, age, race, drinking, smoking, CHD, stroke, creatinine, PIR, education level, TG, marital status, albumin, and uric acid were adjusted. eGDR: estimated glucose disposal rate; ED: erectile dysfunction; PIR: poverty-income ratio; CHD: coronary heart disease; TG: triglycerides; OR: odds ratios; CI: confidence intervals.





**Fig. 3.** Association between eGDR and the risk of ED in various subgroups. eGDR: estimated glucose disposal rate; ED: erectile dysfunction; CI: confidence intervals; OR: odds ratios; BMI: body mass index.



**Fig. 4.** The mediating effect of NLR on the relationship between eGDR and ED. eGDR: estimated glucose disposal rate; ED: erectile dysfunction; CI: confidence intervals; NLR: neutrophil-to-lymphocyte ratio.


**Incremental predictive Value**  
Incorporation of eGDR into the age-only model significantly improved discrimination: the C-statistic increased from 0.846 to 0.853 (DeLong test,  $P < 0.001$ ).

The categorical NRI for the combined eGDR–age model was 3.0% ( $P = 0.016$ ), and the IDI was 1.7% ( $P < 0.001$ ), demonstrating superior performance compared with the age-only model (Table 6 and Fig. 6).

**Table 4.** Mediation analysis of NLR in the association between eGDR and erectile dysfunction, weighted

| Independent variable | Mediator | Total effect            |        | Indirect effect         |       | Direct effect           |        | Proportion mediated, % |
|----------------------|----------|-------------------------|--------|-------------------------|-------|-------------------------|--------|------------------------|
|                      |          | Coefficient (95% CI)    | P      | Coefficient (95% CI)    | P     | Coefficient (95% CI)    | P      |                        |
| eGDR                 | NLR      | -0.171 (-0.240, -0.100) | <0.001 | -0.018 (-0.036, -0.004) | 0.030 | -0.150 (-0.222, -0.079) | <0.001 | 10.3                   |

eGDR: estimated glucose disposal rate; NLR: neutrophil-to-lymphocyte ratio; CI: confidence intervals.



**Fig. 5.** ROC analysis of eGDR, HbA1c, METS-IR, BMI, TyG, WHtR, and WC to ED among American adults. eGDR: estimated glucose disposal rate; HbA1c: hemoglobin A1c; METS-IR: metabolic score for insulin resistance; TyG: triglyceride-glucose index; BMI: body mass index; WC: waist circumference; WHtR: waist to height ratio; ED: erectile dysfunction; ROC: receiver operating characteristic.

#### Sensitivity analysis

To minimize potential confounding and enhance the precision of our findings, we performed an additional sensitivity analysis with a more stringent definition of ED, including only participants who reported being ‘Never able’ to sustain an erection (Table 7). This analysis included 437 ED patients and 3,337 non-ED patients. The association between eGDR and ED remained statistically significant (OR = 0.86, 95% CI: 0.75–0.99).

#### Discussion

In this cross-sectional study of a nationally representative sample of 3,774 participants, we identified a significant inverse association between eGDR and ED, which was

particularly pronounced among individuals with higher educational attainment. Mediation analysis further indicated that NLR partially mediated the eGDR–ED association. Moreover, among the assessed surrogate indices for IR and obesity – including eGDR, HbA1c, METS-IR, TyG, BMI, WC, and WHtR – eGDR demonstrated the highest AUC for predicting ED risk.

Numerous studies have demonstrated an association between IR and the development of ED. A cross-sectional study reported that patients with IR are at significantly increased risk of ED, even after adjustment for confounding variables (20). The hyperinsulinemic–euglycemic clamp (HIEC) is widely regarded as the gold standard for assessing IR (21). However, this method requires frequent arterial blood glucose measurements, which limits its practical applicability (22, 23). Consequently, there is a need for more straightforward and feasible approaches to assess IR in clinical and epidemiological settings.

The eGDR, incorporating readily accessible clinical parameters such as WC, HbA1c, and hypertension status, has been proposed as a simple surrogate marker of IR in individuals with T1DM (9). Prior research has indicated that this alternative method exhibits a high degree of accuracy when compared with gold standard measures (9, 24). eGDR has been identified as an independent predictor of coronary artery disease (25), depression (15), all-cause mortality (26), and peripheral vascular disease (27) in patients with T1DM (28–31). Recent studies have extended the investigation of eGDR’s applicability to non-diabetic patients (32), patients with T2DM (24, 33), and those with acute ischemic stroke (24, 34). Given the shared risk factors between ED and CVD (35), it is plausible to hypothesize an association between eGDR and ED. To our knowledge, this study is the first to investigate this association. Furthermore, the significantly greater AUC for eGDR compared with other IR and obesity surrogate markers indicates its potential clinical utility.

Subgroup analysis revealed that the eGDR–ED association was significantly more pronounced in individuals with higher educational attainment ( $P$  for interaction < 0.001). Previous research has indicated that individuals with sedentary lifestyles and lower educational attainment are more prone to ED (36, 37). Lower educational level is recognized as a risk factor for ED and may exert a greater influence on ED risk than IR within this population. Consequently, the impact of IR on

**Table 5.** The AUC for each index to discriminate erectile dysfunction


| Variable | AUC   | 95% CI      | Cutoff value | Sensitivity | Specificity | Delong P-value |
|----------|-------|-------------|--------------|-------------|-------------|----------------|
| eGDR     | 0.705 | 0.679–0.731 | 8.48         | 0.689       | 0.627       | Reference      |
| HbA1c    | 0.686 | 0.667–0.706 | 5.55         | 0.559       | 0.728       | <0.001         |
| METS-IR  | 0.550 | 0.521–0.579 | 45.26        | 0.451       | 0.646       | <0.001         |
| TyG      | 0.600 | 0.572–0.629 | 8.92         | 0.518       | 0.632       | <0.001         |
| BMI      | 0.521 | 0.501–0.542 | 31.78        | 0.226       | 0.821       | <0.001         |
| WC       | 0.610 | 0.590–0.630 | 100.0        | 0.605       | 0.572       | <0.001         |
| WHtR     | 0.641 | 0.622–0.661 | 0.576        | 0.601       | 0.606       | <0.001         |

eGDR: estimated glucose disposal rate; HbA1c: hemoglobin A1c; METS-IR: metabolic score for insulin resistance; TyG: triglyceride-glucose index; BMI: body mass index; WC: waist circumference; WHtR: waist to height ratio; CI: confidence intervals; AUC: area under the curve.

**Table 6.** Incremental predictive value of eGDR for ED

| Variable | c-statistic          | P         | NRI (95% CI)         | P     | IDI (95% CI)         | P      |
|----------|----------------------|-----------|----------------------|-------|----------------------|--------|
| Age      | 0.846 (0.831, 0.860) | 1.0 (Ref) | 1.0 (Ref)            |       | 1.0 (Ref)            |        |
| +eGDR    | 0.853 (0.839, 0.867) | <0.001    | 0.030 (0.006, 0.055) | 0.016 | 0.017 (0.011, 0.022) | <0.001 |

NRI: net reclassification improvement; IDI: integrated discrimination improvement; eGDR: estimated glucose disposal rate; ED: erectile dysfunction; CI: confidence intervals.



**Fig. 6.** ROC curve analysis for age and eGDR combined age to identify ED. eGDR: estimated glucose disposal rate; ED: erectile dysfunction; ROC: receiver operating characteristic.

ED prevalence may be relatively attenuated in individuals with lower educational levels. Conversely, in more educated populations, who are generally considered healthier and have fewer other potential risk factors, the association between IR and ED is anticipated to be more pronounced. However, educational level is highly correlated with age, which is a well-established independent risk factor for both ED and IR. Therefore, it remains

uncertain whether the observed discrepancy stems from the independent effect of education per se, the confounding influence of age, or unmeasured health-related behaviors.

Our findings indicate that NLR partially mediates the association between IR, as measured by eGDR, and ED, highlighting the importance of monitoring NLR levels in patients with low eGDR. Previous studies have established a significant association between ED and chronic inflammation (38, 39). Consequently, modulating NLR – particularly through reducing neutrophil count and increasing lymphocyte count – may decrease the risk of ED in individuals with low eGDR. These findings enhance our understanding of the complex interrelationships among IR, inflammation, and ED. The cross-sectional nature of biomarker assessment, in which exposure and mediating factors were measured concurrently, and the observational design preclude the establishment of temporal or causal sequences. Therefore, the above interpretation should be regarded as a biologically plausible hypothesis rather than a definitive mechanistic inference.

Two recent studies have utilized the same NHANES 2001–2004 dataset to investigate correlates of ED. Liu et al. reported that NLR was positively associated with ED (OR = 1.35, 95% CI: 1.09–1.68) among 3,610 participants, with monocyte-to-lymphocyte ratio (MLR) demonstrating the highest discriminative accuracy (AUC = 0.616) among inflammatory markers (39). Li et al. identified a positive association between the TyG index and ED prevalence in males aged 20–70 years (7). Our study extends these findings in several important respects. Firstly, whereas Liu et al. treated NLR as the



**Table 7.** Weighted-multivariable logistic regression for the sensitivity analysis between eGDR and ED

| Subgroups       | Model 1           |        | Model 2           |        | Model 3           |       |
|-----------------|-------------------|--------|-------------------|--------|-------------------|-------|
|                 | OR (95% CI)       | P      | OR (95% CI)       | P      | OR (95% CI)       | P     |
| eGDR            | 0.75 (0.70, 0.81) | <0.001 | 0.64 (0.38, 1.05) | <0.001 | 0.86 (0.75, 0.99) | 0.041 |
| eGDR (category) |                   |        |                   |        |                   |       |
| Q1              | I (Ref)           |        | I (Ref)           |        | I (Ref)           |       |
| Q2              | 0.54 (0.35, 0.83) | 0.007  | 0.64 (0.38, 1.05) | 0.075  | 0.88 (0.43, 1.80) | 0.660 |
| Q3              | 0.38 (0.21, 0.68) | 0.002  | 0.51 (0.14, 1.88) | 0.243  | 0.71 (0.29, 1.73) | 0.370 |
| Q4              | 0.10 (0.05, 0.21) | <0.001 | 0.58 (0.28, 1.21) | 0.141  | 0.50 (0.31, 0.78) | 0.004 |
| P for trend     |                   | <0.001 |                   | 0.044  |                   | 0.006 |

Model 1: None covariates were adjusted; Model 2: race and age were adjusted; Model 3, age, race, drinking, smoking, CHD, stroke, creatinine, PIR, education level, TG, marital status, albumin, and uric acid were adjusted. eGDR: estimated glucose disposal rate; ED: erectile dysfunction; CI: confidence intervals; OR: odds ratios; PIR: poverty-income ratio; CHD: coronary heart disease; TG: triglycerides.

primary exposure, our study positions NLR as a mediator in the eGDR–ED pathway, quantifying its mediating proportion at 10.3%. This reframes NLR not merely as an independent predictor but as a partial biological intermediary linking IR to ED. Secondly, the eGDR exhibited markedly superior discriminative performance (AUC = 0.705) compared with both the inflammatory markers evaluated by Liu et al. (AUC = 0.616 for MLR) and the TyG index examined by Li et al., suggesting that eGDR may be a more clinically useful screening tool. These distinctions underscore that while chronic inflammation (as reflected by NLR) and lipid–glucose metabolism (as reflected by TyG) are both relevant to ED pathophysiology, eGDR – by integrating WC, glycemic control, and hypertension status – captures a more comprehensive metabolic profile with greater predictive value.

Several mechanisms may underlie the association between ED and IR. IR is known to enhance the production of inflammatory cytokines and oxidative stress in endothelial cells (40), resulting in significant depletion of NO in tissues exposed to free radicals. The reduction in NO availability subsequently impairs endothelial function (41, 42). Furthermore, endothelin-B receptors have been implicated in elevated reactive oxygen species levels, endothelial dysfunction, and increased vasoconstriction within erectile tissues. Notably, IR has been shown to upregulate endothelin-B receptor expression in the vasculature of obese rats with IR (43). This alteration in endothelial function exacerbates the decline in insulin metabolism, creating a negative feedback loop (21). IR is indicative of pre-diabetes, and its progression toward diabetes parallels the progression of endothelial dysfunction into atherosclerosis (44). Moreover, IR is associated with elevated basal serum insulin levels, which subsequently activate the sympathetic nervous system and increase atherosclerotic risk factors, collectively contributing to ED (45, 46). IR also elevates

endothelin-1 levels – a potent vasoconstrictor affecting both arterial and venous systems – within penile cavernous tissues (47). Under conditions of IR, Leydig cells in the testes produce reduced amounts of testosterone, thereby contributing to ED (48).

This study has several notable strengths. It provides the first investigation of the association between eGDR and ED, while also evaluating its predictive performance for ED relative to various obesity and IR indicators. In addition, we meticulously adjusted for potential confounding variables in the multivariate logistic regression analyses. However, several limitations should be acknowledged. The cross-sectional design inherently precludes causal inference regarding the eGDR–ED association. Moreover, ED was assessed using a self-report questionnaire; although previous studies have confirmed its validity, the severity of ED was not quantified. Erectile function was not assessed using the International Index of Erectile Function-5, which may have introduced sample selection bias. Furthermore, because this study was conducted exclusively in a US sample, additional investigations are needed to determine the generalizability of these findings to populations in diverse geographical regions. Finally, the relatively low prevalence of ED may have resulted in diminished statistical power for certain subgroup analyses.

## Conclusion

This study revealed a significant inverse association between eGDR and ED. Moreover, eGDR demonstrated superior discrimination for ED compared with other surrogate markers of obesity and IR.

## Declarations

## Acknowledgments

The authors are grateful to the NHANES participants and the project staff for their valuable efforts. This work

was supported by the Wenzhou Science and Technology Bureau (Y2023833).

### Ethics approval and consent to participate

The research was performed using de-identified data from the publicly National Health and Nutrition Examination Survey dataset. The National Center for Health Statistics Ethics Review Board approved the survey including humans. Written informed consent was obtained from all participants.

### Availability of data and materials

All raw data were publicly available at the NHANES database (<https://www.cdc.gov/nchs/nhanes/index.htm>).

### Conflict of interest and funding

The authors declare no competing interests. The authors have not received any funding or benefits from industry or elsewhere to conduct this study.

### References

1. Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, et al. Erectile dysfunction. *Nat Rev Dis Primers* 2016; 2: 16003. doi: 10.1038/nrdp.2016.3
2. Shamloul R, Ghanem H. Erectile dysfunction. *Lancet* 2013; 381(9861): 153–65. doi: 10.1016/S0140-6736(12)60520-0
3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. *J Urol* 1994; 151(1): 54–61. doi: 10.1016/S0022-5347(17)34871-1
4. Muneer A, Kalsi J, Nazareth I, Arya M. Erectile dysfunction. *BMJ* 2014; 348: g129. doi: 10.1136/bmj.g129
5. Rosen RC, Wing R, Schneider S, Gendrano N, 3rd. Epidemiology of erectile dysfunction: the role of medical comorbidities and lifestyle factors. *Urol Clin North Am* 2005; 32(4): 403–17, v. doi: 10.1016/j.ucl.2005.08.004
6. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. *J Am Coll Cardiol* 2011; 58(13): 1378–85. doi: 10.1016/j.jacc.2011.06.024
7. Li L, Yao H, Dai W, Chen Y, Liu H, Ding W, et al. A higher TyG index is related with a higher prevalence of erectile dysfunction in males between the ages 20–70 in the United States, according to a cross-sectional research. *Front Endocrinol (Lausanne)* 2022; 13: 988257. doi: 10.3389/fendo.2022.988257
8. Billups KL, Bank AJ, Padma-Nathan H, Katz S, Williams R. Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel. *J Sex Med* 2005; 2(1): 40–50; discussion 50–2. doi: 10.1111/j.1743-6109.2005.20104.1.x
9. Epstein EJ, Osman JL, Cohen HW, Rajpathak SN, Lewis O, Crandall JP. Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes. *Diabetes Care* 2013; 36(8): 2280–5. doi: 10.2337/dc12-1693
10. Meng C, Xing Y, Huo L, Ma H. Relationship between estimated glucose disposal rate and type 2 diabetic retinopathy. *Diabetes Metab Syndr Obes* 2023; 16: 807–18. doi: 10.2147/DMSO.S395818
11. Ren X, Jiang M, Han L, Zheng X. Estimated glucose disposal rate and risk of cardiovascular disease: evidence from the China Health and Retirement Longitudinal Study. *BMC Geriatr* 2022; 22(1): 968. doi: 10.1186/s12877-022-03689-x
12. Kong X, Wang W. Estimated glucose disposal rate and risk of cardiovascular disease and mortality in U.S. adults with pre-diabetes: a nationwide cross-sectional and prospective cohort study. *Acta Diabetol* 2024; 61(11): 1413–21. doi: 10.1007/s00592-024-02305-1
13. Lu Z, Xiong Y, Feng X, Yang K, Gu H, Zhao X, et al. Insulin resistance estimated by estimated glucose disposal rate predicts outcomes in acute ischemic stroke patients. *Cardiovasc Diabetol* 2023; 22(1): 225. doi: 10.1186/s12933-023-01925-1
14. Zipf G, Chiappa M, Porter KS, Ostchega Y, Lewis BG, Dostal J. National health and nutrition examination survey: plan and operations, 1999–2010. *Vital Health Stat* 1 2013; (56): 1–37.
15. Chen Y, Lin H, Xu J, Zhou X. Estimated glucose disposal rate is correlated with increased depression: a population-based study. *BMC Psychiatry* 2024; 24(1): 786. doi: 10.1186/s12888-024-06257-2
16. Li C, Xu J. Negative correlation between metabolic score for insulin resistance index and testosterone in male adults. *Diabetol Metab Syndr* 2024; 16(1): 113. doi: 10.1186/s13098-024-01353-5
17. Huang J, Rozi R, Ma J, Fu B, Lu Z, Liu J, et al. Association between higher triglyceride glucose index and increased risk of osteoarthritis: data from NHANES 2015–2020. *BMC Public Health* 2024; 24(1): 758. doi: 10.1186/s12889-024-18272-9
18. Derby CA, Araujo AB, Johannes CB, Feldman HA, McKinlay JB. Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study. *Int J Impot Res* 2000; 12(4): 197–204. doi: 10.1038/sj.ijir.3900542
19. Zhang X, Wei R, Wang X, Zhang W, Li M, Ni T, et al. The neutrophil-to-lymphocyte ratio is associated with all-cause and cardiovascular mortality among individuals with hypertension. *Cardiovasc Diabetol* 2024; 23(1): 117. doi: 10.1186/s12933-024-02191-5
20. Russo GI, Cimino S, Fragala E, Privitera S, La Vignera S, Condorelli R, et al. Insulin resistance is an independent predictor of severe lower urinary tract symptoms and of erectile dysfunction: results from a cross-sectional study. *J Sex Med* 2014; 11(8): 2074–82. doi: 10.1111/jsm.12587
21. Vasques AC, Novaes FS, de Oliveira Mda S, Souza JR, Yamanaka A, Pareja JC, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. *Diabetes Res Clin Pract* 2011; 93(3): e98–100. doi: 10.1016/j.diabres.2011.05.030
22. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. *Endocr Rev* 1985; 6(1): 45–86. doi: 10.1210/edrv-6-1-45
23. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol* 1979; 237(3): E214–23. doi: 10.1152/ajpendo.1979.237.3.E214
24. Zabala A, Darsalia V, Lind M, Svensson AM, Franzen S, Eliasson B, et al. Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study. *Cardiovasc Diabetol* 2021; 20(1): 202. doi: 10.1186/s12933-021-01394-4
25. Pane A, Conget I, Boswell L, Ruiz S, Vinals C, Perea V, et al. Insulin resistance is associated with preclinical carotid atherosclerosis in patients with type 1 diabetes. *Diabetes Metab Res Rev* 2020; 36(7): e3323. doi: 10.1002/dmrr.3323

26. Nystrom T, Holzmann MJ, Eliasson B, Svensson AM, Sartipy U. Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. *Diabetes Obes Metab* 2018; 20(3): 556–63. doi: 10.1111/dom.13110
27. Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard TJ. Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. *Metabolism* 2002; 51(2): 248–54. doi: 10.1053/meta.2002.30021
28. Dastjerdi P, Hosseini Mohammadi NS, Anaraki N, Rahmati S, Nikfar R, Momeni S, et al. Estimated glucose disposal rate and risk of cardiovascular events in type 1 diabetes: a systematic review and meta-analysis. *Diabetol Metab Syndr* 2025; 17(1): 348. doi: 10.1186/s13098-025-01900-8
29. Vergani M, Borella ND, Rizzo M, Conti M, Perra S, Bianconi E, et al. Metabolic dysfunction-associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: a multi-centre cross-sectional study. *Diabetes Obes Metab* 2025; 27(6): 3201–11. doi: 10.1111/dom.16333
30. Canat MM, Altuntas Y. Comparison of two estimated glucose disposal rate methods for detecting insulin resistance in adults with type 1 diabetes mellitus. *Metab Syndr Relat Disord* 2024; 22(4): 295–301. doi: 10.1089/met.2023.0217
31. Nishtala R, Kietsiriroje N, Karam M, Ajjan RA, Pearson S. Estimated glucose disposal rate demographics and clinical characteristics of young adults with type 1 diabetes mellitus: a cross-sectional pilot study. *Diab Vasc Dis Res* 2020; 17(5): 1479164120952321. doi: 10.1177/1479164120952321
32. Liu C, Liu X, Ma X, Cheng Y, Sun Y, Zhang D, et al. Predictive worth of estimated glucose disposal rate: evaluation in patients with non-ST-segment elevation acute coronary syndrome and non-diabetic patients after percutaneous coronary intervention. *Diabetol Metab Syndr* 2022; 14(1): 145. doi: 10.1186/s13098-022-00915-9
33. Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, et al. Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. *BMC Med* 2021; 19(1): 66. doi: 10.1186/s12916-021-01936-3
34. Xuan J, Juan D, Yuyu N, Anjing J. Impact of estimated glucose disposal rate for identifying prevalent ischemic heart disease: findings from a cross-sectional study. *BMC Cardiovasc Disord* 2022; 22(1): 378. doi: 10.1186/s12872-022-02817-0
35. Nehra A, Jackson G, Miner M, Billups KL, Burnett AL, Buvat J, et al. The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. *Mayo Clin Proc* 2012; 87(8): 766–78. doi: 10.1016/j.mayocp.2012.06.015
36. Yannas D, Zago E, Cavallini E, Todisco T, Vignozzi L, Corona G, et al. Education degree predicts cardiovascular outcomes in men suffering from erectile dysfunction. *Andrology* 2023; 11(6): 1086–95. doi: 10.1111/andr.13389
37. Heidebaugh JJ. Management of erectile dysfunction. *Am Fam Physician* 2010; 81(3): 305–12.
38. Feng X, Mei Y, Wang X, Cui L, Xu R. Association between neutrophil to lymphocyte ratio and erectile dysfunction among US males: a population-based cross-sectional study. *Front Endocrinol (Lausanne)* 2023; 14: 1192113. doi: 10.3389/fendo.2023.1192113
39. Liu H, Dong H, Guo M, Cheng H. Association between inflammation indicators (MLR, NLR, SII, SIRI, and AISI) and erectile dysfunction in US adults: NHANES 2001–2004. *J Health Popul Nutr* 2024; 43(1): 169. doi: 10.1186/s41043-024-00667-4
40. Moon KH, Park SY, Kim YW. Obesity and erectile dysfunction: from bench to clinical implication. *World J Mens Health* 2019; 37(2): 138–47. doi: 10.5534/wjmh.180026
41. Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. *Metabolism* 2000; 49(2): 147–50. doi: 10.1016/S0026-0495(00)91039-4
42. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. *Diabetes Metab Res Rev* 2006; 22(6): 423–36. doi: 10.1002/dmrr.634
43. Katakam PV, Pollock JS, Pollock DM, Ujhelyi MR, Miller AW. Enhanced endothelin-1 response and receptor expression in small mesenteric arteries of insulin-resistant rats. *Am J Physiol Heart Circ Physiol* 2001; 280(2): H522–7. doi: 10.1152/ajpheart.2001.280.2.H522
44. Chen S, Wu R, Huang Y, Zheng F, Ou Y, Tu X, et al. Insulin resistance is an independent determinate of ED in young adult men. *PLoS One* 2013; 8(12): e83951. doi: 10.1371/journal.pone.0083951
45. Musicki B, Hannan JL, Lagoda G, Bivalacqua TJ, Burnett AL. Mechanistic link between erectile dysfunction and systemic endothelial dysfunction in type 2 diabetic rats. *Andrology* 2016; 4(5): 977–83. doi: 10.1111/andr.12218
46. Kara E, Kahraman E, Dayar E, Yetik Anacak G, Demir O, Gidener S, et al. The role of resistin on metabolic syndrome-induced erectile dysfunction and the possible therapeutic effect of Boldine. *Andrology* 2020; 8(6): 1728–35. doi: 10.1111/andr.12853
47. Francavilla S, Properzi G, Bellini C, Marino G, Ferri C, Santucci A. Endothelin-1 in diabetic and nondiabetic men with erectile dysfunction. *J Urol* 1997; 158(5): 1770–4. doi: 10.1016/S0022-5347(01)64125-9
48. Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. *J Clin Endocrinol Metab* 2005; 90(5): 2636–41. doi: 10.1210/jc.2004-2190

---

### \*Feng Chen and Lulu Pan

The Wenzhou Third Clinical Institute

Affiliated to Wenzhou Medical University,

Wenzhou People's Hospital,

Wenzhou city, China

Email: chenfeng19920410@126.com; wzpanlulu@126.com